Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2305 • ACR Convergence 2023
Infection Vulnerability in Pregnant Women with and Without Systemic Lupus Erythematosus
Dr Hiba Khogali¹, Ghada Al‐Bluwi², Virgie Guy² and Ali Al Dhanhani³, ¹Tawam Hospital, Al Ain, United Arab Emirates, ²College of Medicine, UAE University, Al Ain, United Arab Emirates, ³UAE University, Al Ain, United Arab Emirates
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that predominantly affects women of childbearing age. Pregnant women with SLE have higher rates of…
Abstract Number: 2321 • ACR Convergence 2023
Does the Perspective of SLE Patients Match the Expert Opinion and Definitions of Remission and Low Disease Activity State? Prospective Analysis of 500 Patients from a Spanish Multicenter Cohort
CORAL Mourino Rodriguez¹, Jose-Maria Pego-Reigosa², Iñigo Rúa-Figueroa³, Francisco Rubino⁴, Iñigo Hernández-Rodríguez⁵, Raúl Menor-Almagro⁶, Esther Uriarte Isacelaya⁷, Eva Tomero Muriel⁸, TAREK CARLOS SALMAN MONTE⁹, MARIA IRENE CARRION BARBERA⁹, Maria Galindo¹⁰, Esther Rodriguez almaraz¹⁰, Norman Jiménez¹¹, Luis Ines¹² and Irene Altabas Gonzalez¹³, ¹Complejo Hospitalario Universitario de Vigo. IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain, ²Rheumatology, Hospital do Meixoeiro, Vigo, Spain, ³Rheumatology, Hospital de Gran Canaria Doctor Negrin, Las Palmas de Gran Canaria, Spain, ⁴Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain, ⁵Hospital do Meixoeiro. Complejo Hospitalario Universitario de Vigo, Vigo, Spain, ⁶Rheumatology, Hospital Jerez, Puerto De Santa María, Spain, ⁷Hospital Universitario de Donostia, Donostia, Spain, ⁸Rheumatology, Hospital La Princesa, Madrid, Spain, ⁹Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ¹⁰Hospital Universitario 12 de Octubre, Madrid, Spain, ¹¹IIRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute., Vigo, Spain, ¹²Centro Hospitalar e Universitario de Coímbra, Coimbra, Portugal, ¹³Complejo Hospitalario Universitario de Vigo, IRIDIS (Investigation in Rheumatology and Immune-Mediated Diseases) Group, Galicia Sur Health Research Institute, Vigo, Spain
Background/Purpose: There is no information available regarding whether the patient's perception of disease activity aligns with current definitions of DORIS 2021 remission and Lupus Low…
Abstract Number: 2340 • ACR Convergence 2023
Multi-targeted Therapy Better in Achieving Complete Response in Lupus Nephritis: A Systematic Review and Meta-analysis
Omer Pamuk¹, Bisma Shaikh², Saif Khan³, Ali Abbas⁴, Sarah Abi Doumeth⁵ and sarfaraz Hasni⁶, ¹University Hospitals Cleveland Medical Center, Cleveland, OH, ²Jinnah Sindh Medical University, Karachi, Pakistan, ³College of Medical and Dental Sciences, Birmingham, United Kingdom, ⁴Alabama College of Osteopathic Medicine, Dothan, AL, ⁵Case Western Reserve University/University Hospitals Cleveland Medical Center, Cleveland, OH, ⁶Lupus Clinical Trials Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health (NIH), Bethesda, MD
Background/Purpose: The overall management of SLE and Lupus Nephritis (LN) has significantly improved over the last four decades.Recently great therapeutic strides have been made in…
Abstract Number: 2447 • ACR Convergence 2023
Interleukin-6 Activates Glial Cells and Induces Cognitive Dysfunction in Murine Neuropsychiatric Lupus
Joshua Reynolds¹, Michelle Huang¹, Myriam Meineck², Tamara Möckel², Andreas Schwarting² and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²University Medical Center of the Johannes Gutenberg University of Mainz, Mainz, Germany
Background/Purpose: Up to 50% of SLE patients experience neuropsychiatric involvement (neuropsychiatric lupus, or NPLSE) in the form of cognitive deficits, memory loss, depression, and anxiety.…
Abstract Number: 2502 • ACR Convergence 2023
Self-Reported Sleep Disorders Among Individuals with Systemic Lupus Erythematosus
Patti Katz¹, Maria Dall'Era², Jinoos Yazdany³ and Kaleb Michaud⁴, ¹University of California San Francisco, San Rafael, CA, ²University of California San Francisco, San Francisco, CA, ³University of California, General Department of Medicine, Division of Rheumatology, San Francisco, CA, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Research in the general population has linked sleep disorders to poor outcomes such as lower pain thresholds, fatigue, cognitive impairment, depression, and cardiovascular disease…
Abstract Number: 2592 • ACR Convergence 2023
Trends, Sociodemographic and Clinical Factors Associated with Avascular Necrosis and Related Arthroplasties in Hospitalized Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis
Rashmi Dhital¹, Neha Singh², Brian Pedersen² and Christie M. Bartels³, ¹UC San Diego, San Diego, CA, ²University of California San Diego, San Diego, CA, ³University of Wisconsin, School of Medicine and Public Health, Madison, WI
Background/Purpose: Avascular necrosis (AVN) can be a debilitating complication of autoimmune diseases and steroid treatment, with a higher prevalence in systemic lupus erythematosus (SLE) (0.8-33%)…
Abstract Number: 0056 • ACR Convergence 2023
The Activation of cGAS-STING Pathway in Systemic Lupus Erythematosus
Jie An¹, Stephen Wilson², Jill Henault³ and Keith Elkon¹, ¹University of Washington, Seattle, WA, ²Bristol Myers Squibb, Cambridge, MA, ³Bristol Myers Squibb, Acton, MA
Background/Purpose: The majority of patients with SLE show a striking Type I Interferon (IFN-I) signature in their peripheral blood. Although this signature can be generated…
Abstract Number: 0171 • ACR Convergence 2023
A Conceptual Framework to Characterize the Indirect Burden of Systemic Lupus Erythematosus (SLE): Findings from Qualitative Patient Interviews
Vibeke Strand¹, Prajakta Masurkar², Jennifer Reckleff³, Taylor Schwartz⁴, Alison Silverstein⁴, Jennifer Osborne⁴, Josie Lloyd⁴, Brian Leinwand⁴, Elaine Karis⁵, Fatima Barbar-Smiley⁶ and Karen Costenbader⁷, ¹Stanford University, Portola Valley, CA, ²Amgen, Inc., Atlanta, GA, ³Amgen, Inc., Westlake Village, CA, ⁴Inovalon Insights, Bowie, MD, ⁵Amgen, Inc., Colts Neck, NJ, ⁶Amgen, Inc., Dublin, OH, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: SLE is a chronic autoimmune disorder that affects multiple organs and leads to a variety of symptoms, including joint pain, fatigue, and skin rashes,…
Abstract Number: 0212 • ACR Convergence 2023
The Impact of Immunosuppression on the Humoral Immunogenicity of SARS-CoV-2 mRNA Vaccines in SLE
Rebecca Sadun¹, Dan Crair², Emmanuel B Walter³, Jennifer Rogers¹, Megan Clowse⁴, Amanda Eudy⁵, Kai Sun¹, Jayanth Doss¹, Lisa Criscione-Schreiber⁶, Sarah Valencia² and M. Anthony Moody⁶, ¹Duke University, Durham, NC, ²Duke Human Vaccine Institute, Durham, NC, ³Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, ⁴Duke University, Chapel Hill, NC, ⁵Duke University, Raleigh, NC, ⁶Duke University School of Medicine, Durham, NC
Background/Purpose: The ACR's COVID-19 Vaccine Guidance recommends all patients with rheumatic diagnoses be vaccinated against SARS-CoV-2. The predominant SARS-CoV-2 vaccines used in the United States…
Abstract Number: 0549 • ACR Convergence 2023
Development of Customized Digital Cognitive Assessment Battery: A Pilot Use Case in SLE Patients
Priyanka Srivastava¹ and Liza Rajasekhar², ¹International Institute of Information Technology, Hyderabad, India, ²Nizam's Institute of Medical Sciences, Madhapur, India
Background/Purpose: Reported prevalence of cognitive dysfunction (CD) in SLE varies from 3%-88%1.Variability may be due to use of tools insensitive to population characteristics like literacy,…
Abstract Number: 0566 • ACR Convergence 2023
Characterization of Disease Activity Using a Novel Physiologic Biomarker in Pediatric SLE
Sangeeta Sule, Olivia Lamanna, Kevin Jackson, Sun-Young Ahn, Tineer Ahmed and Julia Finkel, Children's National Hospital, Washington, DC
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex inflammatory disease involving many organ systems. To better understand and treat SLE, two phenotypes have been proposed.…
Abstract Number: 0584 • ACR Convergence 2023
Targeting Key Components of SLE Pathogenesis with the Multifaceted Immunomodulatory Properties of Cenerimod, a Selective S1P1 Receptor Modulator
Thomas Hoyler¹, Daniel Strasser¹, Ouali Berkani², Peter Cornelisse¹, Mark Murphy¹ and Marianne Martinic¹, ¹Idorsia Pharmaceuticals Ltd., Allschwil, Switzerland, ²IDORSIA, Allschwil, Switzerland
Background/Purpose: In SLE, aberrant lymphocyte activation and autoantibody production result in deposition of immune complexes and contribute to tissue damage. Cenerimod, a highly selective S1P1…
Abstract Number: 0602 • ACR Convergence 2023
Dual Blockade of ICOS and CD28 with Acazicolcept (ALPN-101) Reveals Non-Redundant Roles of T Cell Co-Stimulation Pathways in Systemic Lupus Erythematosus
Elizabeth Repash, Tiffany Blair, Amanda Enstrom, Lawrence Evans, Susan Debrot, Katherine Lewis, Armand Bankhead, Stanford Peng and Stacey Dillon, Alpine Immune Sciences, Inc., Seattle, WA
Background/Purpose: CD28 and inducible T cell costimulator (ICOS) play nonredundant roles in T cell activation and inhibiting these pathways can ameliorate an (auto)immune response. Systemic…
Abstract Number: 0786 • ACR Convergence 2023
A Retrospective Analysis of the Efficacy of the Euro-Lupus Nephritis Cyclophosphamide Regimen versus NIH Regimen in a South Carolina Lupus Nephritis Cohort
Anna Arar, Diane L. Kamen, Paul Nietert and Melissa Cunningham, Medical University of South Carolina, Charleston, SC
Background/Purpose: Manifestations of systemic lupus erythematous (SLE) vary in severity and presentation; lupus nephritis (LN) affects up to half of SLE patients and confers a…
Abstract Number: 0895 • ACR Convergence 2023
Lipocalin-2 Promotes Cutaneous and Neuropsychiatric Disease in Murine Lupus
Chaim Putterman¹, Elise Mike² and Sayra Garcia¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²Johns Hopkins, Bronx, NY
Background/Purpose: One central mechanism believed to contribute to the pathogenesis of neuropsychiatric systemic lupus erythematosus (NPSLE) is temporary disruption of the blood brain barrier (BBB).…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].